Trabecular bone score in patients with liver transplants after one year of risedronate treatment.
Librizzi S, Guadalix S, et al.Transplant International 2015 [record in progress].
Aims
To analyze the effect of Risedronate (RIS) on Trabecular Bone Score (TBS) in liver transplant patients with low bone mass.
Interventions
Participants were randomised to either RIS group (oral RIS 35 mg once weekly, plus oral calcium and vitamin D3) or control group (calcium and vitamin D3 only)
Participants
89 liver transplant recipients aged ≥ 18 years
Outcomes
The primary outcome measured was TBS. Other measured outcomes were biochemical parameters, bone densitometry and incidence of fractures.
Follow-up
1 year
CET Conclusions
This is a retrospective analysis of an RCT comparing risedronate plus calcium and vitamin D with calcium and vitamin D only (control). The report investigates trabecular bone score (TBS) as a surrogate for predicting the risk of posttransplant vertebral fractures during 1-year follow-up as the utility of using bone mineral density (BMD) scores for predicting fracture risk in liver transplant patients is still unclear. There was no change in TBS during the 1-year follow-up within the groups and there were no differences between groups in TBS during the follow up. The incidence of fractures between groups was not different and there was not relationship between TBS and BMD, and TBS and the incidence of fractures. The usefulness of TBS to predict posttransplant vertebral fractures could not be established by this study.
Data analysis
Available case analysis
Quality notes
Previously reported as Guadalix S, et al. Effect of early risedronate treatment on bone mineral density and bone turnover markers after liver transplantation: a prospective single-center study. Transplant Int 2011; 24 (7): 657-65.
Trial registration
None